US 8541456
Roflumilast for the treatment of diabetes mellitus type 2
granted A61KA61K31/44A61K45/06
Quick answer
US patent 8541456 (Roflumilast for the treatment of diabetes mellitus type 2) held by TAKEDA GMBH expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TAKEDA GMBH
- Grant date
- Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/44, A61K45/06, A61P, A61P13/12